Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7180495

CCOC(C)Oc1ccc(PC(=O)c2c(C)cccc2Cl)c(C)c1.[Li]

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ TP53 P04637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ ITGB1 P05556 4/20 0.32
▸ ITGA4 P13612 4/20 0.32
▸ ITGA2 P17301 1/20 0.32
▸ ITGB7 P26010 1/20 0.32
▸ RORC P51449 1/20 0.31
▸ TRPM4 Q8TD43 1/20 0.31
▸ TYK2 P29597 1/20 0.31
▸ FFAR1 O14842 4/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ MCL1 Q07820 1/20 0.31
▸ ALDH2 P05091 1/20 0.31
▸ MRGPRX4 Q96LA9 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ UTS2R Q9UKP6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7180248 0.97 MEN1 (0.37) MEN1PKMKMT2ATP53MAPT
Lithium SCHEMBL7180677 0.92 SMN1; SMN2 (0.34) MEN1PKMKMT2AFFAR1SMN1; SMN2
Lithium SCHEMBL7177895 0.91 SMN1; SMN2 (0.35) MEN1PKMKMT2ATP53MAPT
SCHEMBL7187636 0.90 TRPM4 (0.32) MEN1PKMKMT2ATP53MAPT
Lithium SCHEMBL7180576 0.89 TYK2 (0.33) MEN1PKMKMT2ATP53MAPT
Lithium SCHEMBL7186703 0.85 TDP1 (0.35) MEN1PKMKMT2ATP53MAPT
SCHEMBL7175370 0.85 ITGB1 (0.34) MEN1PKMKMT2ATP53MAPT
SCHEMBL7187626 0.85 SMN1; SMN2 (0.34) MEN1PKMKMT2ATP53MAPT
SCHEMBL7177496 0.84 TYK2 (0.37) MEN1PKMKMT2ATP53MAPT
Lithium SCHEMBL7174732 0.84 SMN1; SMN2 (0.37) MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MEN1 2312/4885PKM 3848/4885KMT2A 1586/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MEN1 2263/4885PKM 3933/4885KMT2A 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.